On diabetic foot, wound healing, amputation prevention, and the merger of consumer tech with medical devices
In a recent study conducted by a team from the University of California, San Francisco (UCSF), including Iris H. Liu, MD, Rym El Khoury, MD, Jade S. Hiramoto, MD MAS, Warren J. Gasper, MD, Peter A. Schneider, MD, Shant M. Vartanian, MD, and Michael S. Conte, MD, the relevance of the BEST-CLI trial endpoints was... Continue Reading →
Insightful, data-rich commentary as expected from our flowmigos Conte and O'Banion The Battle of the Limb Preservation Trials: BEST-CLI vs. BASIL-2 Two major randomized clinical trials comparing endovascular and open surgical approaches for patients with chronic limb-threatening ischemia (CLTI) - BEST-CLI and BASIL-2 - reported seemingly contradictory results recently. In the larger BEST-CLI trial, patients... Continue Reading →
Another important contribution to the literature from the Best CLI trial from Jeff Syracuse and coworkers. Type of Research: This is prospectively collected data from a randomized clinical trial. Key Findings: Patients presenting with WIfI stage 4 were more often current smokers, had end stage renal disease, diabetes, and were not independently ambulatory. WIfI stage 4, compared... Continue Reading →
This from our colleagues Alik Farber, Matt Menard and Ken Rosenfeld. Likely to be a game-changer in how patients with CLTI are addressed. The first results from the BEST-CLI randomised controlled trial (RCT) of 1,830 patients show that surgical bypass with adequate single-segment great saphenous vein (GSV) is a more effective revascularisation strategy for patients with chronic limb-threatening ischaemia (CLTI) who are deemed to be suitable... Continue Reading →
